Genetics of primary ovarian insufficiency: new developments and opportunities

Yingying Qin
Center for Reproductive Medicine, Shandong Provincial Hospital, Shandong University, National Research Center for Assisted Reproductive Technology and Reproductive Genetics, The Key Laboratory for Reproductive Endocrinology of Ministry of Education, Shandong Provincial Key Laboratory of Reproductive Medicine

Xue Jiao
Center for Reproductive Medicine, Shandong Provincial Hospital, Shandong University, National Research Center for Assisted Reproductive Technology and Reproductive Genetics, The Key Laboratory for Reproductive Endocrinology of Ministry of Education, Shandong Provincial Key Laboratory of Reproductive Medicine

Joe Leigh Simpson
Research and Global Programs March of Dimes Foundation; Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, simpsonj@fiu.edu

Zi-Jiang Chen
Center for Reproductive Medicine, Shandong Provincial Hospital, Shandong University, National Research Center for Assisted Reproductive Technology and Reproductive Genetics, The Key Laboratory for Reproductive Endocrinology of Ministry of Education, Shandong Provincial Key Laboratory of Reproductive Medicine, Jinan 250001, China. Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Follow this and additional works at: https://digitalcommons.fiu.edu/all_faculty

Recommended Citation
Qin, Yingying; Jiao, Xue; Simpson, Joe Leigh; and Chen, Zi-Jiang, "Genetics of primary ovarian insufficiency: new developments and opportunities" (2015). All Faculty. 94.
https://digitalcommons.fiu.edu/all_faculty/94

This work is brought to you for free and open access by FIU Digital Commons. It has been accepted for inclusion in All Faculty by an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.
Genetics of primary ovarian insufficiency: new developments and opportunities

Yingying Qin¹, Xue Jiao¹, Joe Leigh Simpson²,³, and Zi-Jiang Chen¹,⁴,*

¹Center for Reproductive Medicine, Shandong Provincial Hospital, Shandong University, National Research Center for Assisted Reproductive Technology and Reproductive Genetics, The Key Laboratory for Reproductive Endocrinology of Ministry of Education, Shandong Provincial Key Laboratory of Reproductive Medicine, Jinan 250001, China ²Research and Global Programs March of Dimes Foundation, White Plains, NY, USA ³Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA ⁴Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China

*Correspondence address. chenzijiang@vip.163.com

Submitted on March 6, 2015; resubmitted on June 2, 2015; accepted on July 9, 2015

TABLE OF CONTENTS

- Introduction
- Methods
- Results
  - Chromosomal abnormalities in POI
  - Single genes causing non-syndromic POI
  - Pleiotropic single gene disorders in POI
  - Mitochondrial genes causing POI
  - Multiple malformation syndromes characterized by POI
  - Genome-wide studies in POI
  - Regulatory genes and networks
- Conclusion: current status of genes causing POI

BACKGROUND: Primary ovarian insufficiency (POI) is characterized by marked heterogeneity, but with a significant genetic contribution. Identifying exact causative genes has been challenging, with many discoveries not replicated. It is timely to take stock of the field, outlining the progress made, framing the controversies and anticipating future directions in elucidating the genetics of POI.

METHODS: A search for original articles published up to May 2015 was performed using PubMed and Google Scholar, identifying studies on the genetic etiology of POI. Studies were included if chromosomal analysis, candidate gene screening and a genome-wide study were conducted. Articles identified were restricted to English language full-text papers.

RESULTS: Chromosomal abnormalities have long been recognized as a frequent cause of POI, with a currently estimated prevalence of 10–13%. Using the traditional karyotype methodology, monosomy X, mosaicism, X chromosome deletions and rearrangements, X-autosome translocations, and isochromosomes have been detected. Based on candidate gene studies, single gene perturbations unequivocally having a deleterious effect in at least one population include Bone morphogenetic protein 15 (BMP15), Progesterone receptor membrane component 1 (PGRMC1), and Fragile X mental retardation 1 (FMR1) premutation on the X chromosome; Growth differentiation factor 9 (GDF9), Folliculo-genesis specific bHLH transcription factor (FIGLA), Newborn ovary homeobox gene (NOBOX), Nuclear receptor subfamily 5, group A, member 1 (NR5A1) and Nanos homolog 3 (NANOS3) seem likely as well, but mostly being found in no more than 1–2% of a single population studied. Whole genome approaches have utilized genome-wide association studies (GWAS) to reveal loci not predicted on the basis of a candidate gene, but it remains difficult to locate causative genes and susceptible loci were not always replicated. Cytogenomic methods (array CGH) have identified other regions of interest but studies have not shown consistent results, the resolution of arrays has varied and replication is uncommon. Whole-exome sequencing in non-syndromic POI kindreds has only recently begun, revealing mutations in the Stromal antigen...
3 (STAG3), Synaptonemal complex central element 1 (SYCE1), minichromosome maintenance complex component 8 and 9 (MCM8, MCM9) and ATP-dependent DNA helicase homolog (HFH1) genes. Given the slow progress in candidate-gene analysis and relatively small sample sizes available for GWAS, family-based whole exome and whole genome sequencing appear to be the most promising approaches for detecting potential genes responsible for POI.

**CONCLUSION:** Taken together, the cytogenetic, cytogenomic (array CGH) and exome sequencing approaches have revealed a genetic causation in ~20–25% of POI cases. Uncovering the remainder of the causative genes will be facilitated not only by whole genome approaches involving larger cohorts in multiple populations but also incorporating environmental exposures and exploring signaling pathways in intragenic and intergenic regions that point to perturbations in regulatory genes and networks.

**Key words:** primary ovarian insufficiency / premature ovarian failure / chromosomal abnormality / gene mutation / genome-wide association studies / whole-exome sequencing / next generation sequencing

### Introduction

Primary ovarian insufficiency (POI), also known as premature ovarian failure (POF) or premature menopause, is defined as cessation of menstruation before the expected age of menopause. This age is traditionally defined to be prior to 40 years and diagnosis is confirmed by elevated serum FSH levels (>40U/L). Although frequently stated that ~1% of the population is affected with POI before the age of 40 years and 0.1% before age 30 years, the prevalence is actually less certain (Coulam et al., 1986).

The disorder is clearly heterogeneous, with a wide spectrum of causes, namely cytogenetic, genetic, infectious or iatrogenic. Autoimmune and metabolic etiologies may or may not be genetic. Irrespective, etiology remains to be elucidated in most cases and until a decade ago few specific causes were known beyond X-chromosomal abnormalities, Fragile X mental retardation 1 (FMR1) premutation and FSH receptor (FSHR) in the Finnish population (Simpson, 1975; Aittomäki et al., 1995; Wittenberger et al., 2007). Most cases of isolated POI still appear sporadically, but ~10–15% has an affected first-degree relative, indicating significant genetic etiology (Van Kasteren et al., 1999). Pedigrees with multiple affected relatives are not rare (recessive and dominant). Presence of POI as one component of a pleiotropic genetic disorder is also well recognized. Yet identifying precise causative genes has been challenging. Here, we enumerate known genetic causes of POI, most elucidated within the last 5–10 years.

Confusion exists concerning nomenclature, namely the use of POF or POI. It is the view of the authors that POI can be taken to encompass occult, biochemical and overt stages, whereas POF is best considered as only the final stage of POI. The designation POI is thus best reserved as alluding to the entire gamut of disorders having diminished ovarian reserve—occult, subclinical, iatrogenic. Although many authors espouse POI in lieu of POF, the canonical genetic reference—Online Mendelian inheritance in man (OMIM)—has long used, and continues to use POF, to nominate causative genes. These designations now apply to POFI–POF9 (Supplementary Table S1), and the list growing.

### Methods

A search for original articles published up to May 2015 was performed using PubMed and Google Scholar to identify studies on genetic variants associated with the human disease. The key word combinations include ‘premature ovarian failure’, ‘primary ovarian insufficiency’, ‘early menopause’, ‘genetic’, ‘gene mutation’, ‘variant’ and ‘genome wide study’. For a study to be included in our review, it had to focus on chromosomal analysis, candidate gene screening, or a genome-wide study in different POI cohorts. In addition, studies on mitochondrial genes causing POI and multiple malformation syndromes characterized by POI were included. Reports on the role of candidate genes in animal models were not included. Where appropriate, reference lists of identified articles were also searched for further relevant papers. However, articles identified were restricted to English language full-text papers.

### Results

#### Chromosomal abnormalities in POI

Chromosomal abnormalities have long been recognized as a cause of POI, but percentages vary widely among reported series. This clearly reflects biases of ascertainment, for example reflecting whether a cohort was derived from a referral cytogenetic lab, a gynecologic practice, or a pediatric practice. Numerous different karyotypic anomalies have been found, ranging from numerical defects (monosity X; X chromosome mosaicism), X-deletions, X autosomal translocations, and X-isochromosomes and other rearrangements. Aggregate frequency of chromosomal abnormalities in reported studies is summarized in Table I. Small sample sizes as well as selection biases and differing ages of ascertainment probably account for different prevalence in different populations. However, each of the five largest studies with respect to sample size reported frequencies between 10.0 and 12.9% (Zhang et al., 2003; Lakhal et al., 2010a; Baronchelli et al., 2011; Jiao et al., 2012; Kalantari et al., 2013); thus, a prevalence of 10–13% seems reasonable.

#### Numerical defects

The X chromosome has long been known to play an essential role in the maintenance of ovarian development and function. Females lacking an X chromosome as well as those showing an extra X chromosome are predisposed to developing POI.

45,X and 45,X/46,XX

Turner syndrome, often but not universally associated with X monosity, leads to ovarian dysgenesis and accelerated follicular atresia. X monosity without mosaicism is more typically found in primary amenorrhea and cases were almost universally understood to present with this phenotype. However, many early series were recruited from pediatric clinics, not among adult women. In 1975, Simpson (1975) reported that 3% (5/178) of 45,X patients actually menstruated. 45,X/46,XX and other forms of association also are associated with secondary
amennorhea (POI). Either haploinsufficiency of pivotal genes on the X chromosome or non-specific meiotic impairment could explain the accelerated atresia of 45,X oocytes. Variability would be expected given potential heterozygosity of alleles in genes subjected to X-inactivation.

47,XXX
47,XXX women may experience oligomenorrhea, secondary amenorrhea, and early menopause, but relative risk has not been well studied. Goswami et al. (2003) reported the prevalence of 47,XXX in 52 women with POI to be 3.8%, whereas in our much larger Chinese series we observed 1.5% (8/531) (Jiao et al., 2012). The presence of three X chromosomes plausibly leads to meiotic disturbance and, secondarily, ovarian failure. Additionally, overexpression of genes that escape X-inactivation could cause POI in 47,XXX. Mechanisms remain to be defined (Tartaglia et al., 2010). A confounder is that an association exists between 47,XXX and autoimmune diseases (Holland, 2001; Goswami et al., 2003).

X-structural abnormalities and X-autosome translocations
X chromosome deletions and X-autosome balanced translocations have long been observed in POI and were once the only approach available to localize causative genes. This strategy was illustrated in the 1970s by a region on the X chromosome appearing critical for the POI phenotype (Sarto et al., 1973). A critical region was delineated that gave boundaries for breakpoints of X-autosome translocations associated with ovarian failure. This region extends from Xq13-Xq21 (POI2) to Xq23-q27 (POI1). It has been proposed by Rizzolio and colleagues that Xq13-Xq21 governs epigenetic regulations that down-regulate oocyte-expressed autosomal genes (Rizzolio et al., 2006, 2007, 2009).

Irrespective of mechanisms involved in the critical region, almost all terminal deletions originating at Xq13 are associated with primary amenorrhea, lack of breast development and complete ovarian failure (Simpson and Rajkovic, 1999; Simpson, 2008). By contrast, terminal deletions arising at Xq25 or Xq26 are characterized by the more common phenotype being not primary amenorrhea but premature ovarian failure. The gene designation POI1 is applied to this region. The more distal deletions arise at Xq27 or Xq28 and exert a less severe effect on stature and reproductive function than do proximal deletions (Simpson, 1975; Simpson and Rajkovic, 1999). Gene(s) in this POI-causing region are considered distinct from Fragile X mental retardation 1 (FMR1), located at Xq27 and premutation of which is the most common single cause of POI.

Multiple genes on the X chromosome have been identified by X-autosomal translocations. These include Diaphanous-related formin 2 (DIAPH2, Xq22) (Bione et al., 1998), X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound (XPNPEP2, Xq25) (Prueitt et al., 2000), Dachshund family transcription factor 2 (DACH2, Xq21.3) (Prueitt et al., 2002), Premature ovarian failure, 1B (POF1B, Xq21.1) (Lorda-Sanchez et al., 2000; Bione et al., 2004), Choroideremia (CHM, Xq21.1) (Lorda-Sanchez et al., 2000; Mansouri et al., 2008), Progesterone receptor membrane component 1 (PGRMC1, Xq24) (Mansouri et al., 2008), Collagen, type IV, alpha 6 (COL4A6, Xq22.3) (Nishimura-Tadaki et al., 2011) and Nuclear RNA export factor 5 (NXF5, Xq22.1) (Bertini et al., 2010). Some will individually be discussed below.

Autosomal rearrangements
Autosomal translocations—Robertsonian and reciprocal—have been sporadically cases in Belgian, American, Japanese and Chinese women (Hens et al., 1989; Orczyk et al., 1989; Kawano et al., 1998; Jiao et al., 2012). Perturbations presumably confer haploinsufficiency or interrupt pivotal genes in these regions. Non-specific defective meiotic pairing or a position effect on contiguous genes is also a potential explanation (Simpson, 2008; Persani et al., 2009). No autosomal region appears preferentially involved, long frustrating investigators seeking to use breakpoints to localize regions containing autosomal genes of relevance. Searches for autosomal regions disrupted in X-autosome translocations have similarly not proved fruitful in identifying autosomal roles in POI.

Table I Frequency of chromosomal abnormalities (CA) in different population studies.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Frequency of CA (%)</th>
<th>No. of CA</th>
<th>Sample size</th>
<th>Clinical characteristics</th>
<th>Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ayed et al. (2014)</td>
<td>18.0</td>
<td>18</td>
<td>100</td>
<td>PA, SA</td>
<td>Tunisian</td>
</tr>
<tr>
<td>Kalantari et al. (2013)</td>
<td>10.05</td>
<td>18</td>
<td>179</td>
<td>PA, SA</td>
<td>Iranian</td>
</tr>
<tr>
<td>Jiao et al. (2012)</td>
<td>12.1</td>
<td>64</td>
<td>531</td>
<td>PA, SA</td>
<td>Chinese (Jinan, Beijing, Shenzhen)</td>
</tr>
<tr>
<td>Baronechelli et al. (2011)</td>
<td>10.0</td>
<td>27</td>
<td>269</td>
<td>PA, SA, EM</td>
<td>Italian</td>
</tr>
<tr>
<td>Lakhal et al. (2010a)</td>
<td>10.8</td>
<td>108</td>
<td>1000</td>
<td>PA, SA</td>
<td>Tunisian</td>
</tr>
<tr>
<td>Ceylaner et al. (2010)</td>
<td>25.3</td>
<td>19*</td>
<td>75</td>
<td>SA</td>
<td>Turkish</td>
</tr>
<tr>
<td>Janse et al. (2010)</td>
<td>12.9</td>
<td>19</td>
<td>147</td>
<td>SA</td>
<td>Dutch</td>
</tr>
<tr>
<td>Portnoi et al. (2006)</td>
<td>8.8</td>
<td>8</td>
<td>90</td>
<td>PA, SA</td>
<td>French</td>
</tr>
<tr>
<td>Zhang et al. (2003)</td>
<td>12.5</td>
<td>13</td>
<td>104</td>
<td>POI</td>
<td>Chinese (Chongqing)</td>
</tr>
<tr>
<td>Devi and Benn (1999)</td>
<td>13.3</td>
<td>4</td>
<td>30</td>
<td>SA</td>
<td>American</td>
</tr>
<tr>
<td>Davison et al. (1998)</td>
<td>2.5</td>
<td>2</td>
<td>79</td>
<td>PA, SA FSH &gt; 20 IU/l</td>
<td>English</td>
</tr>
<tr>
<td>Castillo et al. (1992)</td>
<td>32.0</td>
<td>15</td>
<td>47</td>
<td>POI</td>
<td>Chilean</td>
</tr>
<tr>
<td>Rebar and Connolly (1990)</td>
<td>25.4</td>
<td>16</td>
<td>63</td>
<td>PA, SA</td>
<td>American</td>
</tr>
</tbody>
</table>

Chromosomal ‘abnormalities’ means visible structural changes in karyotype that are sufficiently large to cause clinical abnormalities. Variants (e.g. prominent satellites) are not included. CA, chromosomal abnormalities; PA, primary amenorrhea; POI, primary ovarian insufficiency; SA, secondary amenorrhea; EM, early menopause.

*Including 246,XY gonadal dysgenesis (Swyer syndrome).
Single genes causing non-syndromic POI

Aside from regions of interest defined by chromosome deletions and translocations, the other traditional strategy to identify candidate genes in POI is to study genes whose product is known and plays a role in human folliculogenesis or shows an organ-specific effect based on murine knockout models (candidate genes). Many genes have been interrogated for these reasons. In this section we specifically review all genes for which data warrant strong consideration as a candidate gene for POI. Table II and Supplementary Table SII contain available details of reported studies.

Variants occurring in evolutionary conserved regions are more likely to carry functional significance. These include missense, nonsense, insertion or deletion variants and were considered as plausible causative variants with clinical significance. Thus, perturbations should yield a severe functional defect. A nonsense mutation that results in truncated protein should lead to haploinsufficiency; a splicing site mutation or insertion/deletion should result in a frameshift that leads to a different protein product; a missense mutation may change the amino acid and cause a dominant negative effect.

Those regions or genes found only by genome-wide studies, including genome-wide association study, cytogenomic study, whole-exome sequencing, and next generation sequencing (NGS), are cited separately.

Genes on the X chromosome

Bone morphogenetic protein 15 (BMP15) (Xp11.2). BMP15 is located on chromosome Xp11.2. The possible involvement of BMP15 in POI pathogenesis was initially supported by evidence from animal models. Inverdale and Hanna sheep with a naturally occurring Bmp15 mutation had increased ovulation rate and twin and triplet births in heterozygotes, but ovarian failure results from impaired follicular development beyond the primary stage in homozygotes (Galloway et al., 2000). Bmp15 knockout female mice also were subfertile, showing decreased ovulation rates, reduced litter size and decreased number of litters per lifetime (Yan et al., 2001).

In humans BMP15 was first implicated in POI by Di Pasquale et al. (2004), who reported a heterozygous p.Y235C missense mutation in each of two sisters having ovarian failure. The authors presented (2004), who reported a heterozygous p.Y235C missense mutation in.

In humans BMP15 was first implicated in POI by Di Pasquale et al. (2004), who reported a heterozygous p.Y235C missense mutation in each of two sisters having ovarian failure. The authors presented an example of two missense mutations (p.T650A and p.O658K) in Indian women with POI (Panda et al., 2010).

Forkhead box O4 (FOXO4) (Xq13.1). The FOXO4 gene encodes a member of the O class of winged helix/forkhead transcription factor family (FOXO). FOXO4 is expressed in granulosa cells in mice and human, and is involved in the PI3K (phosphoinositide 3-kinase)/Akt (v-akt murine thymoma viral oncogene homolog 1)/Cdkn1b (cyclin-dependent kinase inhibitor 1B) molecular pathway, which suggests a functional role in ovarian physiology (Pisarska et al., 2009). Mutation screening in 116 Tunisian patients identified only one intronic variant; IVS2 + 41T > G; therefore, FOXO4 might not be a common cause of POI in the Tunisian population (Fonseca et al., 2012a).

Premature ovarian failure, 1B (POF1B) (Xq21.2). Alluded to previously, this ‘gene’ is actually a region, but codified by OMIM. Its significance is its location within the critical POI region. It was found to be interrupted by a breakpoint in an X-autosome translocation in a patient with secondary amenorrhea (POI). Subsequent mutation analysis in an Italian POI cohort (N = 223) only revealed 30 SNPs (Bone et al., 2004). In a Lebanese family having five sisters with POI, Lacombe et al. (2006) established linkage to Xq21 using whole-genome SNP typing and homozygosity-by-descent mapping. Sequencing identified a homozygous p.R329Q membrane receptor (Losel et al., 2008). This protein is expressed in various tissues, e.g. liver, kidney, adrenal glands, uterus and leukocytes and involves progesterone signaling in the reproductive system (Cahill, 2007; Losel et al., 2008; Mansouri et al., 2008). PGRMC1 mediates progesterone’s anti-apoptotic effects on granulosa cells (Engmann et al., 2006; Peluso et al., 2006; Losel et al., 2008; Mansouri et al., 2008).

Mansouri et al. (2008) identified a mother and daughter with POI, both of whom carried an X-autosome translocation [t(X;11)(q24;q13)]. Systematic mapping of the Xq breakpoint and performing RNA expression studies revealed reduced expression of PGRMC1. Mutation screening of 67 females with idiopathic POI identified a third patient having a missense mutation (p.H165R), located in the cytochrome b5 domain. The p.H165R mutation abolishes binding of cytochrome P450 7A1 (CYP7A1) to PGRMC1 and attenuates PGRMC1’s ability to mediate the anti-apoptotic action of progesterone in ovarian cells. These findings suggest that mutant or reduced levels of PGRMC1 may cause POI through impaired activation of the microsomal cytochrome P450 and increased apoptosis of ovarian cells. A recent study in Chinese patients with POI identified a novel missense mutation (C.556C>T, p. P186S), but there was no functional study to confirm a deleterious effect (Wang et al., 2014b).

Androgen receptor (AR) (Xq12). The AR gene encodes the androgen receptor and is involved in sex differentiation and reproduction. Its perturbation in 46,XY individuals results in the well-known sex reversed phenotype of androgen insensitivity, testosterone produced by testis exerting no effect on androgen-dependent differentiation. In the ovary, AR is expressed in developing follicles, mainly granulosa cells. Deficiency of AR in female mice results in a POI-like phenotype and dysregulation of a number of major genes critical for folliculogenesis, indicating that normal folliculogenesis requires AR-mediated androgen action (Shiina et al., 2006). An association between CAG repeat length in exon 1 of the AR gene and POI has been proposed but remains controversial (Bretherick et al., 2008; Chatterjee et al., 2009; Sugawa et al., 2009; Panda et al., 2010). An example is a repeat of two missense mutations (p.T650A and p.O658K) in Indian women with POI (Panda et al., 2010).
Table II  Variants identified in candidate genes on the X chromosome for idiopathic and sporadic POI.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Location</th>
<th>Cases (N)</th>
<th>Controls (N)</th>
<th>Ethnicity</th>
<th>MR (%)</th>
<th>Sequence variation</th>
<th>Amino acid change</th>
<th>FC</th>
<th>Mechanism</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMP15</td>
<td>Xp11.2</td>
<td>50</td>
<td>214</td>
<td>Caucasian</td>
<td>2 (4.0%)</td>
<td>c.242A&gt;G</td>
<td>p.H81R</td>
<td></td>
<td>Slightly affects transactivation of BRE-luc in COV434 granulosa cells</td>
<td>Tiotiu et al. (2010)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100</td>
<td>100</td>
<td>Chinese</td>
<td>1 (1.0%)</td>
<td>c.985C&gt;T</td>
<td>p.R329C</td>
<td></td>
<td></td>
<td>Wang et al. (2010b)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>300</td>
<td>216</td>
<td>Caucasian</td>
<td>12 (4.0%)</td>
<td>c.913A&gt;C</td>
<td>p.S5R</td>
<td>Yes</td>
<td></td>
<td>Rossetti et al. (2009)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20</td>
<td>93</td>
<td>German</td>
<td>None</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td>Ledig et al. (2008)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>92</td>
<td>76</td>
<td>Chinese</td>
<td>None</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td>Zhang et al. (2007)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>203</td>
<td>54</td>
<td>Caucasian</td>
<td>3 (1.5%)</td>
<td>c.443T&gt;C</td>
<td>p.L148P</td>
<td></td>
<td></td>
<td>Laissue et al. (2006)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>133</td>
<td>197</td>
<td>Indian</td>
<td>14 (10.5%)</td>
<td>c.181C&gt;T</td>
<td>p.R61W</td>
<td>Yes</td>
<td>Decreased mature protein production, weaker Smad1/5/8 phosphorylation in COV434 cells and decreased granulosa cell proliferation</td>
<td>Dixit et al. (2006c) and Inagaki and Shimasaki (2010)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>166</td>
<td>181</td>
<td>Caucasian</td>
<td>7 (4.2%)</td>
<td>c.202C&gt;T</td>
<td>p.R68W</td>
<td></td>
<td></td>
<td>DiPasquale et al. (2004, 2006)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>38</td>
<td>51</td>
<td>New Zealand</td>
<td>None</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td>Chand et al. (2006)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15</td>
<td>3</td>
<td>Japanese</td>
<td>None</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td>Takebayashi et al. (2000)</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Gene</th>
<th>Location</th>
<th>Cases (N)</th>
<th>Controls (N)</th>
<th>Ethnicity</th>
<th>MR*</th>
<th>Sequence variation</th>
<th>Amino acid change</th>
<th>FC</th>
<th>Mechanism</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>POF1B</td>
<td>Xq21.2</td>
<td>223</td>
<td>900</td>
<td>Italian</td>
<td>2 (0.9%)</td>
<td>c.G1477A</td>
<td>p.C444Y</td>
<td></td>
<td></td>
<td>Bione et al. (2004)</td>
</tr>
<tr>
<td>PGRMC1</td>
<td>Xq22-q24</td>
<td>67</td>
<td>153</td>
<td>Swedish Italian</td>
<td>1 (1.5%)</td>
<td>c.494A&gt;G</td>
<td>p.H165R</td>
<td>Yes</td>
<td></td>
<td>Mansouri et al. (2008)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>196</td>
<td>200</td>
<td>Chinese</td>
<td>1 (0.51%)</td>
<td>c.556C&gt;T</td>
<td>p.P186S</td>
<td></td>
<td></td>
<td>Wang et al. (2014b)</td>
</tr>
</tbody>
</table>

MR: mutation rate; FC: functional confirmation; BMP15: bone morphogenetic protein 15; AR: androgen receptor; FOXO4: forkhead box O4; POF1B: premature ovarian failure, 1B; DACH2: dachshund family transcription factor 2; PGRMC1: progesterone receptor membrane component 1.

*Only refer to novel missense, frameshift and nonsense mutations

MR: mutation rate; FC: functional confirmation; BMP15: bone morphogenetic protein 15; AR: androgen receptor; FOXO4: forkhead box O4; POF1B: premature ovarian failure, 1B; DACH2: dachshund family transcription factor 2; PGRMC1: progesterone receptor membrane component 1.

*Only refer to novel missense, frameshift and nonsense mutations
a subset of Chinese women with sporadic POI harbor mutations in FIGLA. Recently, another novel intronic variant was found in 219 Indian POI cases (Tosh et al., 2015). Further functional validation is warranted.

Newborn ovary homebox gene (NOBOX) (7q35). NOBOX is an oocyte-specific homeobox gene that plays a critical role in early folliculogenesis. The causative role was discovered by Rajkovic et al. (2004). In mice, nobox deficiency disrupted early folliculogenesis and oocyte-specific gene expression. Lack of Nobox accelerated post-natal oocyte loss and abolished the transition from primordial to growing follicles in mice. In female mice lacking Nobox, follicles are replaced by fibrous tissue in a manner similar to non-syndromic ovarian failure in women. Genes preferentially expressed in oocytes, including Pou5f1 (POU class 5 homeobox 1) and Gdf9, are also down-regulated in Nobox−/− mice. Letchowska et al. (2011) showed that POI in Nobox-deficient mice results from faulty signaling between somatic and germ line components during embryonic development. In addition, the extremely unusual presence of abnormal adherens junctions between unseparated oocytes within syncytial follicles indicates that faulty communication between somatic and germ cells is involved in, or leads to, abnormalities in the cell adhesion program. Qin et al. (2007a) were the first to demonstrate that a perturbation (p.R355H) in NOBOX was responsible for human POI. The mutation disrupted NOBOX homeodomain binding to NOBOX DNA-binding element (NBE) and had a dominant negative effect. Our functional studies demonstrated that haploinsufficiency was involved in the genetic mechanism in humans for POI. Mutations in the homeobox domain of NOBOX proved not to be a common explanation for POI in Chinese women (0/200) (Qin et al., 2009) but Bouilly et al. (2011, 2015) subsequently reported that novel NOBOX loss-of-function mutations accounted for 6.2 and 5.6%, respectively, of cases in two large ‘primary ovarian insufficiency’ cohorts of Caucasian and African ancestry.

Nuclear receptor subfamily 5, group A, member 1 (NR5A1); Steroidogenic factor-1 (SF-1) (9q33). NR5A1 encodes an orphan nuclear receptor that regulates transcription of an array of genes involved in reproduction, steroidogenesis and male sexual differentiation. These include anti-Mullerian hormone (AMH), Nuclear receptor subfamily 0, group B, member 1 (DAX1), Cytochrome P450, family 11, subfamily A, polypeptide 1 (CYP11A), steroidogenic acute regulatory protein (StAR), as well as genes encoding steroid hydroxylases, gonadotrophins, and aromatase. Inactivation of Nr5a1 specifically in mouse granulosa cells causes infertility associated with hypoplastic ovaries.

Philibert et al. (2010) identified NR5A1 mutations as a frequent cause of ‘primary amenorrhea’ in 46,XY phenotypic female adolescents with a low testosterone concentration. Lourenco et al. (2009) sequenced NR5A1 in four families (each having at least one family member with a 46,XY disorder of sex development and another with 46,XX POI) and 25 subjects with sporadic POI, and they identified 19 different mutations in the NR5A1 gene. Functional studies indicated that these mutations substantially impaired the transactivation activity of NR5A1. Subsequently additional mutations were identified in different ethnicities with low frequencies (Supplementary Table SII). Janse et al. (2012) sequenced the coding regions of NR5A1 in a large, well-phenotyped cohort of 356 Dutch women with POI, finding 9 different mutations in 10 patients. Functional prediction showed low to intermediate pathogenicity for all non-conserved mutations. However, the novel p.Y5D mutation, detected in a non-domain region, was presumed to result in haploinsufficiency in Chinese patients with POI (Jiao et al., 2013).

FSH receptor (FSHR) (2p21-p16). FSH/FSHR signaling plays a key role in normal gonadal function by regulating follicular growth, estrogen production and oocyte maturation. Mutation in FSHR was the first autosomal molecular explanation for POI, elucidated prior to the contemporary era. Aittomäki (1994) and Aittomäki et al. (1995, 1996) ascertained 75 primary or secondary amenorrhea cases, and found homozygous mutations (c.566C>T, p.A189V), in the extracellular portion of this G-protein receptor, in women of six Finnish families with hypergonadotropic ovarian dysgenesis. This mutation resulted in a dramatic reduction of binding capacity and signal transduction, but with apparently normal ligand-binding affinity (Aittomäki et al., 1995). The frequency of the c.566C>T mutation is 0.96% in a Finnish population (Jiang et al., 1998). However, subsequent screening in cohorts of different ethnicities seldom found mutations (da Fonte Kohek et al., 1998; Jiang et al., 1998; Conway et al., 1999; Takakura et al., 2001; Tong et al., 2001; Sundblad et al., 2004; Chen et al., 2006; Ledig et al., 2008; Viloindre et al., 2008; Prakash et al., 2009; Woad et al., 2013). Therefore, FSHR mutations are not uncommon in XX gonadal dysgenesis in Finland, but apparently rare elsewhere (Supplementary Table SII).

TGF, beta receptor III (TGFBR3) (1p33-p32). Human TGFBR3 is located at 1p33-p32 and encodes the TGF-β type III receptor. The encoded receptor is a membrane proteoglycan that often functions as a co-receptor with other TGF-β receptor superfamily members. Two missense variants, p.E459G and p.P825L, were identified in Chinese women with idiopathic POI, both predicted to have functional and structural impacts on the TGFBR3 protein (Qin et al., 2011). Another missense mutation—p.P775S—was found in an Indian POI case (Dixit et al., 2006b).

G protein-coupled receptor 3 (GPR3) (1p36.1-p35). The GPR3 gene, located in 1p36.1-p35 and having 2 exons, is a member of the G protein-coupled receptor family. Predominantly expressed in oocytes, GPR3 maintains meiotic arrest in antral follicles until the LH surge through pathways involved in cAMP and cGMP regulation. In Gpr3−/− mice, the majority of oocytes in antral follicles had unscheduled premature resumption of meiosis (Mehlmann et al., 2004). A synonymous variant (c.135G>A, p.V45V) was found in one Chinese patient (Zhou et al., 2010), and another study also failed to find any potential disease-associated changes in 82 North American Caucasian women with POI (Kovanci et al., 2008).

Wingless-type MMTV integration site family, member 4 (WNT4) (1p36.23-p35.1). WNT4 encodes a secreted extracellular signaling protein that is expressed in human ovaries early in fetal development (Jaaskelainen et al., 2010), and plays a critical role in female sex determination and differentiation. In the ovaries of Wnt4 mutant mice, the rate of apoptosis was similar to that of wild type mice at birth; however, apoptotic cells progressively increased during follicular development (Jaaskelainen et al., 2010). By sequencing the coding region of WNT4 in 55 Tunisian women with POI, a synonymous variant in exon 2 (c.99G>A, p.S33S) was identified (Lakhal et al., 2012). Mutational analysis was also performed in 145 Chinese women with POI with no causative variants found (Chen et al., 2011b).
Inhibins: inhibin, alpha (INHA) (2q35); inhibin, beta A (INHBA) (7p15-p13); inhibin, beta B (INHBB) (2cen-q13). Inhibin is a dimeric glycoprotein hormone. Belonging, like BMP-15 and GDF9, to the superfamily of TGF-β, inhibin is a negative regulator of FSH. Inhibin encompasses inhibin, alpha (INHA) (2q35), inhibin, beta A (INHBA) (7p15-p13), and inhibin, beta B (INHBB) (2cen-q13).

The missense mutation c.769G>A (p.A257T) in the INHA gene was more frequently found in patients with POI in New Zealand (7%) (Shelling et al., 2000), India (11.2%) (Dixit et al., 2004) and Italy (4.5%) (Marozzi et al., 2002). Increased susceptibility to POI was associated with impaired inhibin B bioactivity (Chand et al., 2007). The additional novel missense mutations c.275G>A (p.S92N), c.525C>G (p.H175Q) and c.545C>A (p.A182D) were exclusively identified in Indian POI patients (1.25% for each mutation) (Dixit et al., 2006a). It is unclear whether polymorphisms in the INHA promoter result in reduced inhibin expression, but the promoter variant c.-16C>T was significantly under-represented in patients with POI in New Zealand (Harris et al., 2005). The INHA and INHBB gene encode inhibin αA and inhibin βB subunits. Caustive mutations were not found in the two genes, however, except possibly for one synonymous mutation c.1032C>T in the INHBA gene (Shelling et al., 2000; Chand et al., 2010).

POU class 5 homeobox 1 (POUSF1) (6p21.3). The POUSF1 transcription factor gene, located on 6p21.31, is significantly down-regulated in Nobox knockout mice. Thus, POUSF1 becomes a potential candidate gene for POI, a downstream target of NOBOX. Wang et al. (2011) sequenced 175 Chinese POI cases and found one non-synonymous variant (p.P137T), a heterozygous hydrophobic to hydrophilic substituion.

MutS homolog 4 (MSH4) (1p31) and MSH5 (6p21.3). MSH4 and MSH5 belong to the DNA mismatch repair gene family, playing pivotal roles in meiotic recombination. Mammalian MSH4 and MSH5 proteins form a heterodimeric complex and exert essential functions for normal chromosome synapsis during zygotene. Disruption of Msh4 or Msh5 in female mice resulted in sterility, degenerated ovaries and progressive loss of oocytes due to meiotic failure (de Vries et al., 1999; Kneitz et al., 2000). In a case—control study in a Caucasian population, in which both genes were sequenced, a heterozygous mutation p.P29S in MSH5 was found in 2 of 41 cases. The mutation was located in the Hmsh4-binding domain of MSH5 which could disrupt the integrity of the protein interaction between MSH5 and MSH4 (Mandon-Pepin et al., 2008).

Forkhead box O3 (FOXO3) (6q21). Forkhead transcription factor FOXO3, located at 6q21, encodes a master regulator and potent suppressor of primordial follicle activation. Loss of FOXO3 function in mice leads to POI due to global follicle activation (Liu et al., 2007). The frequency of variants in POI patients differs in different ethnic groups (Supplementary Table SII), but in several populations the frequencies of FOXO3 variants are not insignificant (6% in French and 13.3% in Chinese). However, the pathological role of these variants needs to be determined by functional studies.

Cyclin-dependent kinase inhibitor 1B (CDKN1B) (12p13.1-p12). CDKN1B, also known as P27 and KIP1, encodes a cyclin-dependent kinase inhibitor that regulates proliferation and differentiation in many tissues. It suppresses ovarian follicle endowment and activation, and promotes follicle atresia. Premature follicle depletion occurred due to accelerated activation in Cdkn1b knockout mice (Rajareddy et al., 2007). Sequence analysis of CDKN1B found one novel heterozygous mutation c.356T>C
Genetics of primary ovarian insufficiency

(p.119T) in one of 87 Tunisia POI patients (Ojeda et al., 2011). However, no variants were identified in Chinese cohorts (Wang et al., 2010a; Zhao et al., 2013), suggesting that mutations in CDKN1B are not common in POI, at least in this population.

Anti-Mullerian hormone receptor, type II (AMHR2) (12q13). AMHR2 encodes a receptor in the AMH pathway which plays a crucial role in the development and maintenance of reproductive organs in mammals. Polymorphism c.-482 A>G (rs2002555) in AMHR2 was revealed to be associated with age at menopause in interaction with parity in Dutch women, but no association was found with POI in Korean and Chinese women (Yoon et al., 2013; Qin et al., 2014b). Negative results in AMHR2 were also reported in 16 Japanese women with POI (Wang et al., 2002). However, Qin et al. (2014b) identified two novel missense mutations (p.I209N and p.L354F) in a cohort of Chinese POI women.

Forkhead box O1 (FOXO1) (13q14.1). FOXO1, another member of the forkhead family of transcription factors, is important in granulosa cell function and follicle maturation. Watkins et al. (2006) identified one 5′UTR mutation (c.-30C>T) and one missense mutation (p.P84L) in 60 New Zealand and Slovenia POI patients.

Spalt-like transcription factor 4 (SALL4) (20q13.2). SALL4, a zincfinger transcription factor, is expressed in murine oocytes. SALL4 binds to POU5F1 and could regulate its expression. Both Sall4 and Pou5f1 are drastically down-regulated in Nbox knockout newborn ovaries (Zhang et al., 2006; Choi et al., 2007). Wang et al. (2009) screened the coding regions of SALL4 in 100 Han Chinese females with non-syndromic POI and identified two heterozygous missense mutations (p.V181M and p.T817A) in 100 Han Chinese females with non-syndromic POI (Wang et al., 2002). However, Qin et al. (2014b) identified two novel missense mutations (p.I209N and p.L354F) in a cohort of Chinese POI women.

Meiotic protein covalently bound to DSB (SPO11) (20q13.31). SPO11 of these variants. These may or may not be POI-associated gene fied two heterozygous missense mutations (p.V181M and p.T817A) in SALL4 in 100 Han Chinese females with non-syndromic POI and identified two novel missense mutations (p.I209N and p.L354F) in a cohort of Chinese POI women.

Anti-Mullerian hormone receptor, type II (AMHR2) (12q13). AMHR2 encodes a receptor in the AMH pathway which plays a crucial role in the development and maintenance of reproductive organs in mammals. Polymorphism c.-482 A>G (rs2002555) in AMHR2 was revealed to be associated with age at menopause in interaction with parity in Dutch women, but no association was found with POI in Korean and Chinese women (Yoon et al., 2013; Qin et al., 2014b). Negative results in AMHR2 were also reported in 16 Japanese women with POI (Wang et al., 2002). However, Qin et al. (2014b) identified two novel missense mutations (p.I209N and p.L354F) in a cohort of Chinese POI women.

Forkhead box O1 (FOXO1) (13q14.1). FOXO1, another member of the forkhead family of transcription factors, is important in granulosa cell function and follicle maturation. Watkins et al. (2006) identified one 5′UTR mutation (c.-30C>T) and one missense mutation (p.P84L) in 60 New Zealand and Slovenia POI patients.

Spalt-like transcription factor 4 (SALL4) (20q13.2). SALL4, a zincfinger transcription factor, is expressed in murine oocytes. SALL4 binds to POU5F1 and could regulate its expression. Both Sall4 and Pou5f1 are drastically down-regulated in Nbox knockout newborn ovaries (Zhang et al., 2006; Choi et al., 2007). Wang et al. (2009) screened the coding regions of SALL4 in 100 Han Chinese females with non-syndromic POI and identified two heterozygous missense mutations (p.V181M and p.T817A) in the conserved region. These may or may not be POI-associated gene variants. Further studies are needed to determine the functional effect of these variants.

Meiotic protein covalently bound to DSB (SPO11) (20q13.31). SPO11 is involved in meiosis, forming the double-strand breaks (DSBs) that initiate meiotic recombination. SPO11+/− mice are infertile with premature depletion of oocyte because of defective meiosis. However, no novel variants were found in 41 women with non-syndromic POI (Mandon-Pepin et al., 2008). It is not clear whether an association between SPO11 mutation and sporadic POI exists in human.

DNA meiotic recombinase 1 (DMC1) (22q13.1). Genes perturbing meiosis are logical candidates for non-syndromic POI. DMC1 encodes a member of the superfamily of recombinases, which are important for repairing double-strand DNA breaks during mitosis and meiosis. Among 41 French women with POI, Mandon-Pepin et al. (2008) found one POI case with homozygous mutation p.M200V. However, a subsequent screening revealed no mutation but two known SNPs in 192 Chinese women with POI (Wang et al., 2012).

Pleiotropic single gene disorders in POI

Distinct from non-syndromic POI, pleiotropic Mendelian disorders may manifest POI as part of their phenotypic spectrum. Indeed, the most common single genetic explanation for POI is represented by such a disorder—premutation for fragile X syndrome (Table III).

Fragile X syndrome: familial mental retardation 1 (FMR1) (Xq27.3). Perturbations of FMR1 are responsible for fragile X syndrome. Clinical features include mental retardation, characteristic facial features with large ears and prominent jaw, connective tissue findings (joint laxity), large testes after puberty, and behavioral abnormalities. Fragile X syndrome occurs in males when CGG repeats number above 200. In females ~70% of women with >200 CGG repeats show intellectual disability (de Vries et al., 1996). The incidence of fragile X syndrome in males is approximately 1 in 4000, and in females 1 in 8000 (ACOG committee opinion, 2006a).

The normal number of CGG repeats in FMR1 is 32. Thereafter, there is a stage (premutation) in which 54–200 CGG repeats exist. Pathogenic effects including mental retardation and ataxia may exist, as well as POI. About 15–20% of women with a FMR1 premutation develop POI (Wittenberger et al., 2007). Conversely, 5% of sporadic cases and 10–15% of familial cases in the Caucasian population are explained by FMR1 premutations. For reasons that are not clear, the number of CGG repeats significantly correlates with risk of POI only within selected ranges. There is only a slightly increased risk of expansion associated with 40–79 repeats; but higher risk with 80–99 repeats, yet no further increased risk occurs after >100 repeats, and as noted POI is not observed with the full mutation (>200 CGG) (Allingham-Hawkins et al., 1999). One possible explanation is that certain genes are suppressed in the 54–100 premutation range and link to POI, whereas other genes become suppressed only with higher numbers of CGG repeats. Perhaps, then, phenotypes in the two groups differ because some ovarian genes are inhibitory and others are the converse. Thus, ovarian function may be initially suppressed but later return to normal function.

Given the comparatively higher frequency of premutation of FMR1 in POI than the general population (Supplemental Table SIII), FMR1 testing has become part of the work-up for women with POI. It is formally recommended in Europe (Foresta et al., 2002; European Society of Human Genetics; European Society of Human Reproduction and Embryology, 2006b). In other populations the prevalence is lower. Guo et al. (2014) reported that only 2 premutation carriers were found in 379 sporadic Chinese POI cases (0.49%); none were found in 402 controls. The frequency in Chinese women is thus considerably lower than in Caucasian women (3.3–6.7%). Frequencies are 1.56% in Japanese (Ishizuka et al., 2009) and 1.56% in Japanese (Ishizuka et al., 2003).

Blepharophimosis-ptosis-epicanthus syndrome (BPES): forkhead box L2 (FOXL2) (3q23). Blepharophimosis-ptosis-epicanthus syndrome (BPES) is a pleiotropic autosomal dominant syndrome in which FOXL2 is perturbed and premature ovarian failure occurs (Crisponi et al., 2001). That FOXL2 plays a key if not the pivotal role in ovarian development initially came from study of BPES kindreds. More than one hundred unique FOXL2 mutations have now been described in BPES in different populations (Beyen et al., 2004). By contrast, constitutional mutations are uncommon but...
<table>
<thead>
<tr>
<th>Gene</th>
<th>Location</th>
<th>Mendelian syndrome</th>
<th>Somatic features</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>FMR1</td>
<td>Xq27.3</td>
<td>Fragile X syndrome</td>
<td>Attention deficits, hyperactivity, social deficits, anxiety disorder, deficits in cognitive flexibility.</td>
<td>Reiss and Hall (2007) and Spath et al. (2010)</td>
</tr>
<tr>
<td>FOXL2</td>
<td>3q23</td>
<td>Blepharophimosis-ptosis-epicanthus BPE type I syndrome, BPES I</td>
<td>BPES type I is a complex eyelid malformation associated with POI. The major features of the eyelid malformation involve (i) narrowed horizontal aperture of the eyelids (blepharophimosis), (ii) drooping of the upper eyelid (ptosis), (iii) the presence of a fold of skin arising from the lower eyelid that runs inward and upward (epicanthus inversus), and (iv) lateral displacement of the inner canthi (telecanthus).</td>
<td>Zlotogora et al. (1983) and Oley and Baraitser (1988)</td>
</tr>
<tr>
<td>GALT</td>
<td>9p13</td>
<td>Galactosemia</td>
<td>Cataracts, speech defects, poor growth, poor intellectual function, neurologic deficits (preponderantly extrapyramidal findings with ataxia).</td>
<td>Schadewaldt et al. (2004)</td>
</tr>
<tr>
<td>AIRE</td>
<td>21q22.3</td>
<td>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome, APECED</td>
<td>Candidiasis, Addison’s disease, hypoparathyroidism, type I diabetes, alopecia, vitiligo, ectodermal dystrophy, celiac disease and other intestinal dysfunctions, chronic atrophic gastritis, chronic active hepatitis, autoimmune thyroid disorders, pernicious anemia.</td>
<td>Fierabracci et al. (2012)</td>
</tr>
<tr>
<td>EIF2B</td>
<td>EIF2B2</td>
<td>Central nervous system leukodystrophy and ovarian failure, ovarioleukodystrophy</td>
<td>Neurological disorder characterized by involvement of the white matter of the central nervous system. When Leukodystrophies associated with premature ovarian failure referred to as ovarioleukodystrophy.</td>
<td>Mathis et al. (2008)</td>
</tr>
<tr>
<td>POGL</td>
<td>15q25</td>
<td>Progressive external ophthalmoplegia, PEO</td>
<td>Manifestations range from involvement limited to the eyelids and extracocular muscles.</td>
<td>Graziewicz et al. (2007)</td>
</tr>
<tr>
<td>NOG</td>
<td>17q22</td>
<td>Proximal symphalangism, SYM1</td>
<td>Ankylosis of the proximal interphalangeal joints.</td>
<td>Kosaki et al. (2004)</td>
</tr>
<tr>
<td>PMM2</td>
<td>16p13</td>
<td>PMM2-CGD CDG-1 (a previously known as congenital disorder of glycosylation type Ia)</td>
<td>Cerebellar dysfunction (ataxia, dysarthria, dysmetria), non-progressive cognitive impairment, stroke-like episodes, peripheral neuropathy with or without muscle wasting, absent puberty in females, small testes in males, retinitis pigmentosa, progressive scoliosis with truncal shortening, joint contractures, and premature aging</td>
<td>Sparks and Krasnewich (2005)</td>
</tr>
<tr>
<td>HSD17B4</td>
<td>5q21</td>
<td>Perrault syndrome, PS</td>
<td>Sensorineural deafness in both males and females, and neurological manifestations in some patients.</td>
<td>Jenkinson et al. (2013), Morino et al. (2014), Pierce et al. (2011), Pierce et al. (2013) and Pierce et al. (2010)</td>
</tr>
<tr>
<td>HARS2</td>
<td>5q31.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAR5</td>
<td>19p13.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LARS2</td>
<td>3p21.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C10orf2</td>
<td>10q24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BLM</td>
<td>15q26.1</td>
<td>Bloom syndrome</td>
<td>Chromosomal breakage leading to early onset of aging, short stature and elevated rates of most cancers.</td>
<td>Ellis and German (1996)</td>
</tr>
<tr>
<td>WRN</td>
<td>8p12</td>
<td>Werner syndrome</td>
<td>Premature aging of the skin, vasculature, and bone and elevated rates of certain cancers, particularly sarcomas.</td>
<td>Epstein et al. (1966)</td>
</tr>
<tr>
<td>RECQL4</td>
<td>8q24.3</td>
<td>Rothmund–Thomson syndrome, RTS</td>
<td>Cutaneous rash, sparse hair, small stature, skeletal and dental abnormalities, cataracts, premature aging, and an increased risk for cancer, especially malignancies originating from bone and skin tissue.</td>
<td>Wang et al. (2001)</td>
</tr>
</tbody>
</table>

FMR1: Fragile X mental retardation 1; FOXL2: forkhead box L2; GALT: galactose 1-phosphate uridyl transferase; AIRE: autoimmune regulator; EIF2B: eukaryotic translation initiation factor; POLG: polymerase (DNA directed), gamma; NOG: noggin; PMM2: Phosphomannomutase 2; HSD17B4: Hydroxysteroid (17-beta) dehydrogenase 4; HARS2: Histidyl-tRNA synthetase 2, mitochondrial; CLPP: caseinolytic mitochondrial matrix peptidase proteolytic subunit; LARS2: leucyl-tRNA synthetase 2, mitochondrial; C10orf2: Chromosome 10 open reading frame 2; BLM: Bloom syndrome, RecQ helicase-like; ATM: ATM serine/threonine kinase, WRN: Werner syndrome, RecQ helicase-like; RECQL4: RecQ protein-like 4.
reported in non-syndromic POI. Perhaps 2–3% of isolated POI cases have a FOXL2 mutation (De Baere et al., 2002; Harris et al., 2002) (Supplementary Table SII).

**Galactosemia: galactose 1-phosphate uridyl transferase (GALT)** (9p13)

Galactosemia is caused by deficiency of galactose 1-phosphate uridyl transferase (GALT). Ovarian failure is a common long-term complication in girls and women with galactosemia, first described by Kaufman and coworkers (Kaufman et al., 1979, 1981), who observed POI in 12 of 18 (67%) galactosemic women. Later Waggoner et al. (1990) reported that 17% (8/47) galactosemic women presented with ovarian failure. However, with regard to duarte galactosmia, a mild variant of GALT deficiency, no apparent ovarian dysfunction was reported (Badik et al., 2011). Pathogenesis involves excess galactose toxicity that impairs folliculogenesis, induces resistance to gonadotrophins and accelerates follicular atresia (Fridovich-Keil et al., 2011; Banerjee et al., 2012).

**Carbohydrate-deficient glycoprotein syndrome type I (CDG-la): phosphomannomutase 2 (PMM2)** (16p13)

In type 1 carbohydrate-deficient glycoprotein deficiency, also named phosphomannomutase deficiency, mannose-6-phosphate cannot be converted to mannose-1-phosphate. This lipid linked oligosaccharide is necessary for formation of secretory glycoproteins. Neurologic abnormalities and ovarian failure occur (de Zegher and Jaeken, 1995; Kristianson et al., 1995). Located on 16p13, PMM2 is typically caused by a missense mutation (Bjursell et al., 1997).

**Proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1): noggin (NOG)** (17q22)

NOG encodes a secreted polypeptide that binds to and inactivates members of the TGF-β superfamily (i.e. BMP2, 4, 7, 14 and GDF5). NOG is expressed in various tissues including female reproductive organs. NOG mutations are known to explain proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) (Gong et al., 1999). In addition, Kosaki et al. (2004) described a heterozygous mutation (p.E48K) in NOG in a female presenting with SYM1 and also having POI. However, Laissue et al. (2007) concluded the relationship between NOG mutations and non-syndromic POI was not clear, having screened the coding sequence of NOG in 100 non-syndromic sporadic POI patients and identifying only one heterozygous mutation (p.G92E) (Supplementary Table SII). Actually this experience mirrors the situation involving other pleiotropic genes causing POI.

**Autoimmune regulation/autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED): autoimmune regulator (AIRE)** (21q22.3)

The AIRE gene can if perturbed lead to multi-system abnormalities: alopecia, vitiligo, keratopathy, malabsorption, hepatitis and mucocutaneous candidiasis. Ovarian hypoplasia often occurs, usually in the third decade (Wang et al., 1998). Many different AIRE perturbations have been found in this autosomal dominant disorder, not only nonsense mutations but also frame shifts. No particular mutation leads to ovarian failure as distinct from other autoimmune phenomena. AIRE mutations have not yet been sought in women with isolated POI (non-syndromic).

**Ovarian leukodystrophy: eukaryotic translation initiation factor (EIF2B): subunit 2 beta, 39 kDa (EIF2B2) (1q42.4); subunit 4 delta, 67 kDa (EIF2B4) (2p23.3); subunit 5 epsilon, 82 kDa (EIF2B5) (3q27.1)

‘Vanishing white matter’ leads to variable but progressive neurological degeneration. Ovarian failure may coexist (Schiffmann et al., 1997; Boltschauer et al., 2002). That the causative gene (EIF2B) allows denatured stress-related proteins to accumulate makes plausible the relevance to oogenesis, given ongoing oocyte degeneration. Fogli et al. (2003) found variants in EIF2B2, EIF2B4 and EIF2B5 in seven POI cases with neurologic abnormalities, but in 93 non-syndromic POI none were found positive (Fogli et al., 2004). Therefore, EIF2B genes have not yet been shown to be responsible for non-syndromic POI.

**Perrault syndrome: hydroxysteroid (17-beta) dehydrogenase 4, HSD17B4, 5q21; histidyl-tRNA synthetase 2, mitochondrial, HARS2, 5q31.3; leucyl-tRNA synthetase 2, mitochondrial, LARS2, 3p21.3; caseinolytic mitochondrial matrix peptidase proteolytic subunit, CLPP, 19p13.3; chromosome 10 open reading frame 2, C1orf2, 10q24

Perrault syndrome is a well-recognized pleiotropic autosomal recessive disorder characterized by ovarian failure in females, progressive sensorineural deafness in both males and females, and in some patients, neurological manifestations. Only recently have the underlying genes been identified and proved to be heterogeneous. In a family of mixed European ancestry with two sisters presenting with Perrault syndrome, compound heterozygous variants - c.650A>G (p.Y217C) and c.1704T>A (p.Y568X), in HSD17B4 were found. Then with similar genomic strategies with linkage analysis or whole-exome sequencing (WES), mutations in HARS2, LARS2, CLPP and C10orf2 have been found in the context of Perrault syndrome (Pierce et al., 2011, 2013; Jenkinson et al., 2013; Morino et al., 2014). All these genes are essential for normal mitochondrial function. This group of causative genes is detailed in ‘Mitochondrial Genes Causing POI’ Section.

**Other pleiotropic disorders**

Table III lists other nuclear genes causing syndromes in which POI is a feature. These include POLG associated with progressive external ophthalmoplegia (PEO, detailed in ‘Mitochondrial Genes Causing POI’ section), BLM with Bloom syndrome, AIRE with Ataxia telangiectasia, WRN with Werner syndrome and RECQL4 with Rothmund–Thomson syndrome. A common feature of several is chromosomal breakage, best exemplified by Bloom syndrome (Simpson and Elias, 2003; Simpson, 2014).

In aggregate these and other conditions in Table III explain no more than 1% of cases of POI. From a scientific perspective however, elucidating the role these genes play in reproduction offers novel clues to integrity needed for normal ovarian differentiation. Clinicians caring for females with these syndromes should thoroughly investigate and evaluate any reported menstrual irregularities.

**Mitochondrial genes causing POI**

Perturbations of mitochondrial genes or nuclear genes affecting mitochondria are good candidates for POI because the mature oocyte has the greatest number of mitochondria of any human cell. Mature oocytes readily accumulate mitochondria during oogenesis, mitochondrial biogenesis
playing an essential role in oocyte maturation, fertilization and embryo development. Dysregulation of mitochondrial dynamics contributes to excess oxidative stress and initiation of apoptosis, thus accelerating follicle depletion. A marked quantitative decrease of mitochondrial DNA (mtDNA) in oocytes and peripheral blood cells has been well documented in women with ovarian insufficiency (May-Panloup et al., 2005; Bonomi et al., 2012). Thus, any gene affecting mitochondria involving muscular and neurological disturbance is a candidate, because these systems are so dependent on mitochondrial integrity. Genes governing mitochondrial functions may be located in the nucleus, like those discussed in ‘Single Genes Causing Non-syndromic POI’ section, or in mitochondria itself (mtDNA). To date, those of relevance to POI have been nuclear genes.

Progressive external ophthalmoplegia (PEO): polymerase (DNA directed), gamma (POLG) (15q25)

mtDNA mutations usually affect muscular and neurological systems. In progressive external ophthalmoplegia (PEO) clinical features are proximal myopathy, sensory ataxia and parkinsonism. The causative mutation lies in the gene encoding polymerase gamma (POLG), which is responsible for mtDNA replication and repair. In three of seven families studied by Luoma et al. (2004), PEO cosegregated with PEO. A p.Y955C mutation in POLG was found in two of these three families. p.Y955C (tyrosine to cysteine) affects a highly conserved region, rendering functional plausibility. Compound heterozygosity (N468D/A1105T) was observed by Pagnamenta et al. (2006) in another 3-generation family in which multiple family members were affected with both PEO and POI. Mutation screening of POLG in isolated PEO, has, however, yielded few perturbations. A single p.R953C mutation was found in 201 PEO cases (0.5%) cumulatively reported by Tong et al. (2010). No novel mutations were identified in Italian and British women with PEO (Pagnamenta et al., 2006; Bonomi et al., 2012; Duncan et al., 2012) (Supplementary Table SII). Therefore, POLG variation is not a common explanation for sporadic POI in the absence of clinical suspicion for other mitochondrial-associated physical signs.

Perrault syndrome: HARS2, 5q31.3; LARS2, 3p21.3; CLPP, 19p13.3; C10orf2, 10q24

As reviewed in ‘Pleiotropic Single Gene Disorders Having POI’ Section, ovarian failure is one of the characterized features in Perrault syndrome in females. The genes listed encode mitochondrial tRNA synthetase, chambered protease and primase-helicase and have been found to harbor mutations responsible for POI in Perrault syndrome (Pierce et al., 2011, 2013; Jenkinson et al., 2013; Morino et al., 2014). Through WES in a consanguinous Palestinian family and a nonconsanguineous Slovenian family with Perrault Syndrome, homozygous mutations c.1565C>G (p.T522N) and compound heterozygous mutation c.1077delT and c.1886C>T (p.T629M) in the LARS2 gene were identified, respectively (Pierce et al., 2013). WES was also performed in a nonconsanguineous family of mixed European ancestry, showing compound heterozygous mutations c.598C>G (p.L200V) and c.1102G>T (p.V368L) in the HARS2 gene (Pierce et al., 2011). The homozygous mutations c.433A>C (p.T145P), c.440G>C (p.C147S) and c.270+4A>G in the CLPP gene were observed in three consanguineous Pakistani families with Perrault Syndrome (Jenkinson et al., 2013). In a Japanese family, affected individuals carried compound heterozygous p.R391H and p.N585S in the C10orf2 gene essential for replication of mtDNA; meanwhile compound heterozygous mutations p.W441G and p.V507I were responsible for this disease in another family of European ancestry (Morino et al., 2014).

In aggregate, the above supports a critical role for genes controlling mitochondria in the maintenance of ovarian function and their roles in non-syndromic POI warrant further investigation.

Multiple malformation syndromes characterized by POI

In other syndromes, POI or primary ovarian failure (gonadal dysgenesis) is accepted as one component but the causative gene has not been found. Supplementary Table SIV lists these conditions. Of particular interest is POI associated with cerebellar ataxia (Simpson, 2013).

Genome-wide studies in POI

Contemporary genetic strategies applied to locate susceptible loci or genes causing POI have extended beyond suspected candidate gene interrogations to genome-wide approaches. Approaches include linkage analysis in families with multiple affected members, CGH for CNV, genome-wide association studies (GWAS), genome-wide sequencing of exomes (WES) and, in the future, whole genome sequencing (WGS).

GWAS

In GWAS, also known as whole genome association study (WGAS), one examines many common genetic variants in different individuals to see if any variant is associated with a trait. In GWAS one searches agnostically through the entire genome to identify variants (SNPs) more common in cases than controls of similar ethnicity. No a priori expectations exist. Six GWAS have been performed to identify variants associated with POI, but not all adhered to accepted criteria. Sample sizes were often very small and replicates not sought (Table IV). The first GWAS showed association with the PTH-responsive B1 gene (PTHB1) in a small discovery set of 24 women and 24 controls (Kang et al., 2008). Knauff et al. (2009) identified an association of an intron SNP in ADAM metallopeptidase with thrombospondin type I motif, 19 (ADAMTS19) with POI in a discovery set of only 99 Dutch women and 181 controls; no replication set existed. Laminin, gamma 1 (LAMC1) was then reported to be significantly associated with POI in Korea in 122 cases versus 242 controls (Pyun et al., 2012).

Our group conducted the largest GWAS with an initial discovery set of 391 cases versus 895 controls; the independent replication set consisted of 400 cases and 800 controls. The most significant association was at 8q22.3 (1.6 × 10⁻⁶–3.86 × 10⁻⁶). This falls short of the canonical 10⁻⁸ expected to confer unequivocal significance. This region does not contain a protein coding candidate gene (Qin et al., 2012b). However, it is now appreciated that 90% of significant GWAS associations are in intragenic or intergenic regions, portions of the 98.5% of the genome not coding for protein. These regions include a host of regulatory genes and networks (ENCODE). 8q22.3 may be an important yet undefined long-distance regulatory region affecting ovarian differentiation and oogenesis. Disruption might lead to ovarian failure, analogous to disruption of the region upstream of Sex determining region Y-box 9 (SOX9) that causes XY sex reversal in mice and humans (Qin et al., 2003, 2004). Replication in independent cohorts needs to be performed to determine potential causative roles.

GWAS have revealed multiple loci potentially associated with POI in Chinese, Korean, and Dutch women. However, in each it was difficult
to implicate specific novel genes, and in none did significance exceed $10^{-6}$; positive findings were not always replicated. The most likely explanation for these data is limitation based on small sample size. In no study did sample number exceed 1000, thus lacking statistical power sufficient to detect a modest association when evaluating hundreds of thousands of SNPs. That POI is a rarer condition than polycystic ovary syndrome or endometriosis makes it difficult to accrue the requisite sample size possible in studying those disorders (Uno et al., 2010; Chen et al., 2011a; Shi et al., 2012).

**GWAS involving family linkage analysis**

Table IV includes two genome-wide association linkage studies involving single extended families. In a Dutch POI family subjected to a genome-wide linkage scan 5q14.1-q15 was found to be a susceptibility region (Oldenburg et al., 2008). Caburet et al. (2012) performed genome-wide linkage and homozygosity analysis in a large consanguineous Middle-Eastern POI-affected family showing autosomal inheritance. Two regions—7p21.1-p15.3 and 7q21.3-q22.2—were identified as candidate regions by homozygosity mapping. However, sequencing the two regions—7p21.1-p15.3 and 7q21.3-q22.2—was identified as candidate regions by homozygosity mapping. However, sequencing the three most plausible candidate genes in this region—DLX5, DLX6 and DSS1—failed to reveal mutations.

**GWAS involving age of menopause**

Insights derived from shared genetic susceptibility between POI and either age at natural menopause (AANM) or early menopause (EM) represent another potential path identifying novel entry points for unraveling genetic mechanism involved in POI. Thus, we gathered 36 SNPs shown from previous GWAS studies seeking SNPs associated with AANM or EM, plus 3 additional SNPs in ESR1 and 2 additional SNPs in PTHB1. Differential association was then sought in 371 POI and 800 controls, all of Chinese Han origin (Qin et al., 2012c). Three SNPs, rs2278493 in hexokinase 3 (HK3), rs2234693 in estrogen receptor 1 (ESR1) and rs12611091 in BR serine/threonine kinase 1 (BRSK1), showed nominally significant association with POI. Thus, a plausible relationship could exist between POI and ESR1, BRSK1, HK3.

**Cytogenomic studies (CNV)**

There is increasing interest toward whole genome studies based on CNVs. Using CGH, one can efficiently search for small duplications or deletions potentially associated with a complex trait (such as POI). The purpose of identifying CNVs is that they may contain or be linked to a causative gene for the disorder studied. Seven array CGH studies have identified CNVs associated with POI (Supplementary Table SV). In 2009, Aboura et al. (2009) reported that 8 previously known CNVs in 99 POI French patients located near 5 potential candidate genes—Dynein, axonemal, heavy chain 5 (DNAH5), NLR family, apoptosis inhibitory protein (NAIP), Dual specificity phosphatase 22 (DUSP22), Nuclear protein, transcriptional regulator, 1 (NUPR1), and AKTI. However, this and all other CGH studies have the major pitfall of usually lacking information on parents. A large, de novo, CNV deletion is more likely to be pathogenic than an inherited CNV. Another array CGH study involving 74 German patients with POI or ovarian dysgenesis identified 44 losses or gains at autosomes and X chromosome that might explain POI (Ledig et al., 2010). McGuire et al. (2011) identified 17 novel microduplications and 7 novel microdeletions among 89 POI patients, all but one located at autosomes. Included were two novel microdeletions causing haploinsufficiency for Synaptosomal complex central element protein 1 (SYCE1) and Cytoplasmic polyadenylation element binding protein 1 (CPEB1), genes known to cause ovarian failure in knockout mouse models (Bolcun-Filas et al., 2009; Novoa et al., 2010). Recently,

---

**Table IV** Genome-wide association studies for POI.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discovery set</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of cases</td>
<td>24</td>
<td>99</td>
<td>391</td>
<td>24</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>No. of controls</td>
<td>24</td>
<td>181</td>
<td>895</td>
<td>24</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Associations in discovery set</td>
<td><strong>PTHB1</strong> at 7p14 showed strongest association.</td>
<td><strong>Ht1: GAAAG</strong> POI-susceptible haplotype;</td>
<td><strong>Ht2: TGTGC</strong> POI-resistant haplotype.</td>
<td><strong>rs246246 mapped to ADAMTS19 intron</strong></td>
<td><strong>DSS1: split hand/foot malformation (ectrodactyly) type 1.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Replication set</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of cases</td>
<td>101</td>
<td>60</td>
<td>400</td>
<td>98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of controls</td>
<td>87</td>
<td>90</td>
<td>800</td>
<td>218</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Results of replication set</td>
<td><strong>PTHB1</strong> associated with POI; <strong>Ht1</strong> confers susceptibility to POI.</td>
<td>Association not confirmed.</td>
<td>Frequencies of 9 SNPs and 1 haplotype were higher in POI than in control.</td>
<td><strong>Sequencing three candidate genes DLX5, DLX6 and DSS1 did not reveal causal mutations.</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
a high-resolution array CGH identified eleven unique CNVs in 11 patients with POI. Among these CNVs, a tandem duplication of 475 bp containing 3 NOBOX-binding elements and an E-box important for GDF9 gene regulation in the promoter of GDF9 is likely causative of POI (Norling et al., 2014).

Using a complete X chromosome tiling path array, Quilter et al. (2010) found 15 novel discrete X chromosome intervals in 20/42 (48%) women with POI in the UK. However, in patients from New Zealand, Dudding et al. (2010) detected only two microduplications (Xp22.33 and Xq13.3) in a low frequency of 4%. Knauff et al. (2011) found one CNV in Xq21.3 to be associated with POI, specifically in a region where Protocadherin 11 X-linked (PCDH11X) and TGFβ-induced factor homeobox 2-like, X-linked (TGF2XLX) are located. Interestingly, no deletions were found in other regions, several considered on the basis of traditional cytogenetic studies to be pivotal (Simpson and Rajkovic, 1999).

Differing array CGH platforms and definitions for pathogenicity probably explain some of the discrepant results among the above studies. Also problematic is the limited sample size and lack of parental studies to exclude a CNV ostensibly associated with POI merely having been transmitted from a normal mother.

WES

Low prevalence and impaired fecundity resulting in limited numbers of POI pedigrees without associated somatic anomalies (non-syndromic) has led to increasing application of WES, another agnostic approach. POI pedigrees without associated somatic anomalies (non-syndromic) result from a normal mother.

WES has identified several genes in POI not previously anticipated. In POI associated with somatic features, causative perturbations have been found by WES for HSB17B4, LARS2, CLPP and C10orf2 in Perrault syndrome (Pierce et al., 2010, 2013; Jenkinson et al., 2013; Morino et al., 2014) (detailed in ‘Mitochondrial Genes Causing POI’ section and Table V). Up to the present, there have been six WES conducted in non-syndromic POI pedigrees. Interestingly, almost all plausible candidate genes identified were involved in meiosis and DNA repair (Table V).

ATP-dependent DNA helicase homolog (HFM1) (1p22.2). HFM1 is a meiotic gene encoding DNA helicase preferentially expressed in germ-line tissues such as testis and ovary, and necessary for homologous recombination and synapsis during meiosis (Tanaka et al., 2006). Hfm1−/− female mice had significantly reduced ovaries and follicle numbers and an increase in stromal cells (Guiraldelli et al., 2013). The recent report by Wang et al. (2014a) identified a compound heterozygous mutation (c.1686-1G>C and c.2651T>G, p.I884S) in the HFM1 gene in two affected Chinese sisters. Screening for HFM1 mutations in a cohort of 69 Chinese women with sporadic POI identified another patient with compound heterozygous mutations (c.2206G>A, p.G736R and c.3929_3930 delinsG, p.P1310R fs*41). These variants were not found in 316 matched controls or databases.

Minichromosome maintenance complex component 8 and 9 (MCM8, 20p12.3; MCM9, 6q22.31). MCM8 and MCM9, recently discovered members of the highly conserved mini-chromosome maintenance proteins (MCM), are genes implicated in homologous recombination and repair of double-stranded DNA breaks. The MCM8/MCM9 complex is required for the resolution of dsDNA breaks that occur during homologous recombination in pachytene of meiosis I. Failure to resolve breaks predictably leads to oocyte death and small or absent ovaries. Mcm8 and Mcm9-deficient mice are infertile and have small gonads due to germ cell depletion (Lutzmann et al., 2012). Recently, Rajkovic and colleagues (AlAsir et al., 2015; Wood-Trageser et al., 2014) discovered homozygous mutations in MCM8 and MCM9 genes in consanguineous families with POI (primary amenorrhea), using WES. One of the two mutations found in MCM9 is c.1732+2T>C, which resulted in abnormal alternative splicing and truncated forms of MCM9 that are unable to be recruited to sites of DNA damage. The other mutation c.394C>T (p.R132*) results in loss of function of MCM9. It is suspected that preferential sensitivity of germline meiosis to MCM9 functional deficiency and compromised DNA repair in the somatic component most likely account for the ovarian failure and short stature. A homozygous mutant c.446C>G (p.P149R) found in MCM8 inhibited recruitment of MCM8 to sites of DNA damage and led to genomic instability. ASNP rs16991615 in MCM8 was also found associated with the age of natural menopause in the GWAS previously discussed (Chen et al., 2012). The role the novel MCM8/MCM9 pathway plays in women with idiopathic POI needs to be explored further.

Stromal antigen 3 (STAG3) (7q22.1). STAG3 encodes a subunit of cohesin, a large protein complex that is essential for proper pairing and segregation of chromosomes during meiosis. A homozygous frameshift mutation resulting from a 1-bp deletion (c.968delC, p.F187fs*7) in STAG3 was identified in a highly consanguineous Palestinian pedigree; in which a 10-Mb region on 7q21.3–22.2 and a 3-Mb region on 7p21.1–15.3 had been previously identified to show significant linkage with the POI phenotype (Cabaret et al., 2012, 2014). Deficiency ofSTAG3 in female mice results in severe and early ovarian dysgenesis, with distinctive lack of oocytes and ovarian follicles. Early meiotic arrest and the centromeric chromosomal cohesion defects were observed in Stag3−/− fetal oocytes providing further evidence that STAG3 is essential for assembly of the meiotic cohesin ring and the synaptonemal complex (Cabaret et al., 2014).

Synaptonemal complex central element 1 (SYCE1) (10q26.3). The SYCE1 gene encodes a component of the synaptonemal complex where paired chromosome homologs closely associate in meiosis (synapsis) before crossover. SYCE1−/− mice were infertile with smaller gonads, and showed loss of follicles in ovaries and postmeiotic cells in testis. Early meiosis arrest at prophaseI followed by cell apoptosis could explain the phenotype (Bolcun-Filas et al., 2009). Different microdeletions of SYCE1 have also been reported in Caucasian and Chinese POI patients (McGuire et al., 2011; Zhen et al., 2013). In a consanguineous Israeli Arab family, a homozygous nonsense mutation (c.613C>T, p.Q205*) in SYCE1 was identified in two sisters with primary amenorrhea, presumably inherited in autosomal recessive fashion (de Vries et al., 2014).

Eukaryotic translation initiation factor 4E nuclear import factor 1 (eIF4ENIF1) (22q11.2). eIF4ENIF1, a transport protein, plays an important role in repressing translation through eIF4E. Both genes appear to play important roles in ovarian germ cell development (Villaescusa et al., 2006). A heterozygous nonsense mutation (c.1286C>G, p.S429*) was identified in eIF4ENIF1, segregating with ovarian insufficiency (menopause age 29–35 years) in a large French Canadian family. No additional mutations were identified in eIF4ENIF1 or eIF4E in 38 unrelated women with isolated POI. Haploinsufficiency or nuclear sequestration might disrupt the development of a normal oocyte complement (de Vries et al., 2014).
(continued)

Table V  Whole-exome sequencing for syndromic or isolated POI.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Location</th>
<th>Mutation</th>
<th>Function</th>
<th>Compound Het/Homo/Het</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSB17B4</td>
<td>5q21</td>
<td>c.650A&gt;G (p.Y217C); c.1704T&gt;A (p.Y568X)</td>
<td>Reduced expression with mutant protein</td>
<td>Compound heterozygous</td>
<td>Pierce et al. (2010)</td>
</tr>
<tr>
<td>CLPP</td>
<td>19p13.3</td>
<td>c.433A&gt;C (p.T145F), c.440G&gt;C (p.C147S)</td>
<td>Alter the structure of the CLPP barrel chamber that captures unfolded proteins and exposes them to proteolysis</td>
<td>Homozygous</td>
<td>Jenkinson et al. (2013)</td>
</tr>
<tr>
<td>LARS2</td>
<td>3p21.3</td>
<td>c.270+4A&gt;G</td>
<td>Partially functional in Yeast complementation assay</td>
<td>Homozygous</td>
<td>Pierce et al. (2013)</td>
</tr>
<tr>
<td>C10orf2</td>
<td>10q24</td>
<td>c.1172G&gt;A (p.R391H)</td>
<td>Affect interactions of the linker domain</td>
<td>Homozygous</td>
<td>Monno et al. (2014)</td>
</tr>
<tr>
<td>HFM1</td>
<td>1p22.2</td>
<td>c.1686-1G&gt;C</td>
<td>Partially functional in Yeast complementation assay</td>
<td>Homozygous</td>
<td>Wang et al. (2014a)</td>
</tr>
<tr>
<td>MCM9</td>
<td>6q22.31</td>
<td>c.1732+2T&gt;C</td>
<td>Abnormal splicing and truncated protein that are unable to be recruited to sites necessary for DNA damage</td>
<td>Homozygous</td>
<td>Wood-Trageser et al. (2014)</td>
</tr>
<tr>
<td>STAG3</td>
<td>7q22.1</td>
<td>c.394C&gt;T (p.R132*)</td>
<td>Repair of chromosome breaks impaired in lymphocytes</td>
<td>Homozygous</td>
<td>Caburet et al. (2014)</td>
</tr>
<tr>
<td>SYCE1</td>
<td>10q26.3</td>
<td>c.613C&gt;T (p.Q205*)</td>
<td>Affect interactions of the linker domain</td>
<td>Homozygous</td>
<td>de Vries et al. (2014)</td>
</tr>
<tr>
<td>elf4FEN1</td>
<td>22q11.2</td>
<td>c.1286C&gt;G (p.S429*)</td>
<td>Abnormal splicing and truncated protein that are unable to be recruited to sites necessary for DNA damage</td>
<td>Heterozygous</td>
<td>Kasippillai et al. (2013)</td>
</tr>
</tbody>
</table>

HSD17B4: Hydroxysteroid (17-beta) dehydrogenase 4; CLPP: Caselodinctx mitochondrial matrix peptide proteolytic subunit; LARS2: leucyl-tRNA synthetase 2, mitochondrial; C10orf2: Chromosome 10 open reading frame 2; HFM1: ATP-dependent DNA helicase homolog; MCM8, MCM9: minichromosome maintenance complex component 8 and 9; STAG3: stromal antigen 3; SYCE1: synaptonemal complex central element; elf4FEN1: eukaryotic translation initiation factor 4E nuclear import factor 1.

The whole exome studies in familial POI mentioned above mainly involve genes crucial during meiosis, such as generating and repairing DSBs, chromosome synopsis and recombination, and sister chromatid cohesion. This implies that perturbation of genes encoding proteins that regulate meiosis can result in autosomal recessive primary ovarian insufficiency in humans. Despite some negative candidate gene results that regulate meiosis can result in autosomal recessive primary ovarian insufficiency, this implies that perturbation of genes encoding proteins involved in meiosis, such as generating and repairing DSBs, chromosome synapsis and recombination, and sister chromatid cohesion may affect the outcome of meiosis. This is supported by the study of Qin et al. (2015) who reported a study of 12 POI cases having non-syndromic POI and 176 control women whose menopause had occurred after age 50 years. A further 345 women from the same ethnic origin were stated to be recruited to assess allele frequency for potentially deleterious sequence variants. In the 12 POI cases, complete coding regions of 70 candidate genes were fully sequenced with mutations claimed in ADAMTS19, BMPR2 and LHCGR genes. Full details are awaited.

NGS

Future studies on targeted candidate genes of POI can be anticipated using NGS. A recent abstract (Fonseca et al., 2015) reported a study of 12 POI cases having non-syndromic POI and 176 control women whose menopause had occurred after age 50 years. A further 345 women from the same ethnic origin were stated to be recruited to assess allele frequency for potentially deleterious sequence variants. In the 12 POI cases, complete coding regions of 70 candidate genes were fully sequenced with mutations claimed in ADAMTS19, BMPR2 and LHCGR genes. Full details are awaited.

Regulatory genes and networks

Seeking POF genes has to date largely focused on coding variants, presuming plausible protein disruption. However, only 1.5% of the genome is protein-coding. Indeed, many POF-associated variants in whole genome studies map within, or in linkage disequilibrium to, intronic or intergenic regions; thus, these regions likely contain causative regulatory genes or networks. In our own POI GWAS, for example, ‘gene desert’ 8q22.3 was the region of most significance by association (Qin et al., 2012).

Non-coding variants must be more robustly interrogated. Perturbations sought should include involving non-coding RNA (microRNA [miRNA], long non-coding RNA [lncRNA]), disruption or creation of alternative splicing or transcription factor-binding sites, and epigenetic modifications (DNA methylation patterns, chromatin modification). Large epigenetic consortia, such as ENCODE (http://genome.ucsc.edu/ENCODE/), Roadmap (http://www.roadmapepigenomics.org/) and iHEC (http://www.ihec-epigenomes.org/) point to approaches used to characterize the regulatory landscape of susceptibility regions for specific cell types. Unfortunately, ENCODE (Birney et al., 2007; ENCODE Project Consortium, 2012; Stamatoyanopoulos et al.,
bypassed the reproductive track (males and females), and thus an ovarian ENCODE does not yet exist.

In order to generate the reproductive ENCODE, human ovarian tissue of specific cell types must be studied. Then, differences in regulatory genes between affected and normal individuals can be determined. Massive parallel sequencing using RNA-seq, or Methyl-seq will facilitate a systematic study of the transcriptome in ovaries in relation to genotypes and variants in POI. Chromatin immunoprecipitation followed by sequencing (ChIP-Seq) and RNA-Seq can also help identify novel transcriptional and epigenetic regions and, hence, mechanisms that potentially underlie POI. To analyze the complete proteomes and quantification of post-translational modifications, mass spectrometry would be the most attractive approach.

Having accumulated the requisite information, network and pathway-based analyses of assembled datasets can be assembled using systems biology approaches. Cascades of transcriptional regulation can be evaluated simultaneously, identifying overlap among genes or putative networks that currently constrain key variables in model systems.

The ultimate proof that an identified variant has a pathological effect traditionally relies on constitutive or conditional knock in/out or cell lines with a mutation signature. Increasingly, other approaches will be utilized. Patient-specific induced pluripotent stem cells (iPSCs) lines might offer an individually targeted genetic model system to identify and manipulate pathologic pathway. Use of iPSCs should be of particular value in assessing regulatory genes, which may have a quantitative deleterious effect rather than ‘all or none’ qualitative effect, observed or assumed, in missense or nonsense protein-coding mutations.

**Conclusion: current status of genes causing POI**

The POI—causative genes surveyed and found to date allow us to reach several conclusions.

First, many genes have emerged as POI candidates (Fig. 1), but in nonsyndromic POI only a minority have been proven equivocally causative by functional validation. These include BMP15, PGRMC1, and FMR1 premutation on the X chromosome and on autosomes GDF9, FIGLA, FSHR, NOBOX, NRSN1, NANOS3, STAG3, SYCE1, MCM8/9 and HFM1. No perturbations have been found in a dozen other plausible candidates for which murine knockouts show ovarian failure, but this may simply reflect small sample sizes or interrogation restricted to a single ethnic group.

Second, notable differences in frequency exist among different populations. This is predictable for any genetic condition, and in POI this has already been observed in FSHR, BMP15, NOBOX, FOXL2, TGFBR3, CDKN1B and FOXO3A (Supplementary Table SII). Future genetic studies should involve different ethnic groups and larger sample sizes. Clinically, caution should apply when counseling on the basis of data derived from an ethnic group different from that of the counseled individual.

Third, causative POI genes are increasingly being shown not only to be restricted to expression in ovaries but also expressed ubiquitously. True, POF5 (NOBOX) and POF6 (FIGLA) are restricted to the ovaries. However, PTEN is a major regulator of the PI3K pathway involved in systemic cell proliferation, survival, migration and metabolism. PTEN also plays a vital role in the activation of primordial follicles. The spectrum of candidate genes potentially causing POI is being enriched.

Fourth, many genes that currently appear isolated in function actually may be interrelated within yet to be defined pathways. It is logical to stratify by gene function in ostensibly distinct systems: endocrine, folliculogenesis, cell cycle, meiosis, mitochondrial, as examples. More difficult are gene-gene or protein-protein interactions, acting in ways not yet evident. This review thus unavoidably overestimates the role that protein-coding genes play to the detriment of upstream and downstream regulatory genes. Until recently, exome studies had to be restricted to sequencing individual candidate genes. Continued advances in sequencing techniques and contemporary bioinformatives will facilitate finding additional genes responsible for POI in other portions of the genome.
Fifth, elucidating the etiology and molecular basis of POI is of paramount importance not only in understanding ovarian physiology but also in providing genetic counseling and fertility guidance. Once additional variables are detected, it will be increasingly possible to predict the age of menopause. Women having certain perturbations of POI can be offered the option of oocyte cryopreservation, with later thawing and use in assisted reproductive technology at the appropriate age.

**Supplementary data**

Supplementary data are available at http://humupd.oxfordjournals.org/.

**Authors’ roles**

Y.Q. contributed to literature searching and drafting the article. X.J. participated in literature searching and creating figures and tables. J.L.S. contributed the study design and revised the article critically. Z.-J.C. supervised the study design and revision.

**Funding**

This work was supported by the National Basic Research Program of China (973 program-2012CB944700); the National Natural Science Foundation of China (81270662, 81471509, 81370692, 81370687); the Key Program of National Natural Science Foundation of China (81430029). Funding to pay the Open Access publication charges for this article was provided by National Basic Research Program of China (973 program-2012CB944700).

**Conflict of interest**

None declared.

**References**


Eppig JJ, Jaffe LA. The Gs-linked receptor GPR3 maintains meiotic arrest in primordial germ cells. 


Eppig JJ, Jaffe LA. The Gs-linked receptor GPR3 maintains meiotic arrest in primordial germ cells. 


Hum Genet 2011; 129:156 – 160. 

Norling A, Hirschberg AL, Rodriguez-Wallberg KA, Iwarsson E, Wedell A, Barbaro M. Identification of a duplication within the GDF9 gene and novel candidate genes for primary ovarian insufficiency (POI) by a customized high-resolution array comparative genomic hybridization platform. 


Novoa I, Galligo J, Ferreira PG, Mendes R. Mitotic cell-cycle progression is regulated by CPEB1 and CPEB4-dependent translational control. 


Oldenburg RA, van Dooren MF, de Graaf B, Simons E, Govaerts L, Swagemakers S, Verklerk JM, Oostar BA, Bertoli-Avella AM. A genome-wide linkage scan in a Dutch family identifies a premature ovarian failure susceptibility locus. 


Oley C, Baraitser M. Blepharophimosis, ptosis, epicanthus inversus syndrome (BPES syndrome). 

Genetics of primary ovarian insufficiency


